Latest news with #WajeehKhan
Yahoo
8 hours ago
- Business
- Yahoo
3 Things to Watch Ahead of the Nvidia Annual Meeting on June 25
Nvidia (NVDA) shares are keeping calm ahead of the AI darling's shareholder meeting scheduled for June 25 as the chipmaker is unlikely to deliver fireworks at its upcoming annual event. Still, there are three key things that investors will be watching on the coming Wednesday. Ahead of the shareholder meeting, NVDA stock is up more than 60% versus its year-to-date low set in April. The Next Trillion-Dollar Boom? 3 Stocks to Buy with 300 Million Humanoid Robots on the Horizon. Is Tesla a Buy or Sell as TSLA Stock Zooms on Austin Robotaxi Launch? These 3 Stocks Have Been Hot in 2025. Should You Sell Them Now Before It's Too Late? Stop Missing Market Moves: Get the FREE Barchart Brief – your midday dose of stock movers, trending sectors, and actionable trade ideas, delivered right to your inbox. Sign Up Now! Nvidia shareholders will vote to re-elect the company's board at the annual event on June 25. With no contested seats and a strong performance backdrop, the current directors are expected to cruise to reappointment on Wednesday. Additionally, investors will be watching advisory vote on executive compensation or what is more broadly known as 'say-on-pay.' NVDA CEO Jensen Huang earned nearly $50 million in fiscal 2025 – up roughly 47% from the prior year, largely driven by stock rewards. While the vote is non-binding, it helps with gauging investor sentiment toward Nvidia's leadership amidst its AI-fuelled surge. Lastly, shareholders will vote to ratify PwC as Nvidia's independent auditor on June 25. NVDA has been lucrative for investors over the past three months, but Redburn analysts continue to see significant further upside in the AI stock. On Monday, they maintained the chips giant at 'Buy,' saying its Q2 earnings release will likely 'confirm rising networking attach rates.' Plus, the quarterly update will indicate 'smooth transition to Blackwell Ultra B300s' and pave the way for Nvidia stock to print a new high by the end of 2025, the investment firm told clients in its research note. Redburn currently has a $178 price target on NVDA shares, which indicates potential for another 25% upside from current levels. Wall Street remains bullish at large heading into NVDA's annual shareholder meeting on June 25. According to Barchart, consensus rating on the company based out of Santa Clara, California remains at 'Strong Buy' with the mean target of about $175 suggesting potential upside of more than 20% from here. On the date of publication, Wajeeh Khan did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
10 hours ago
- Business
- Yahoo
Novo Nordisk Just Axed Its Deal with Hims & Hers. Should You Buy the Dip in HIMS Stock?
Hims & Hers (HIMS) shares tanked more than 30% on Monday after pharmaceutical behemoth Novo Nordisk (NVO) terminated its distribution agreement with the telehealth company. Novo Nordisk agreed to a high-profile partnership with HIMS to distribute Wegovy, its blockbuster weight-loss treatment. The Next Trillion-Dollar Boom? 3 Stocks to Buy with 300 Million Humanoid Robots on the Horizon. Is Tesla a Buy or Sell as TSLA Stock Zooms on Austin Robotaxi Launch? These 3 Stocks Have Been Hot in 2025. Should You Sell Them Now Before It's Too Late? Our exclusive Barchart Brief newsletter is your FREE midday guide to what's moving stocks, sectors, and investor sentiment - delivered right when you need the info most. Subscribe today! But the Danish giant axed that deal today, citing concerns that Hims & Hers has been selling unapproved compounded formulations of that drug on its online platform. Including today's plunge, Hims & Hers stock is down more than 35% versus its year-to-date high. Novo Nordisk's announcement this morning is disconcerting for Hims & Hers investors because the deal was broadly seen as the latter's gateway into the booming weight-loss market. Offering access to Wegovy via a $599-per-month bundled plan could have resulted in a meaningful boost to its revenue, especially as GLP-1 drugs reshape obesity care. However, not only did the telehealth firm lose that growth catalyst today, it now faces reputational damage and regulatory scrutiny as well over its compounded drug practices. Together, this could make it incrementally more difficult for HIMS shares to recover in the second half of 2025. Investors should practice caution in buying the dip in Hims & Hers stock on Monday also because – even without the loss of Wegovy – the company's management guided for weaker-than-expected Q2 sales. In May, the telehealth firm said its revenue will fall between $530 million and $550 million in the second quarter – short of the nearly $565 million that experts had forecast. And now that HIMS has lost Wegovy deal as well, its financials will likely take a more pronounced hit moving forward. That's part of the reason why BofA currently rates Hims & Hers shares at 'Sell.' Its analysts' $28 price target on the San Francisco-headquartered firm warns of another 35% down side from here. The consensus rating on Hims & Hers stock currently sits at 'Hold' only. While analysts have a mean target on HIMS set at about $48 at writing, suggesting potential upside of more than 10% from here – investors should note that they could downwardly revise their estimates following NVO news in the coming weeks. On the date of publication, Wajeeh Khan did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
10 hours ago
- Business
- Yahoo
Fiserv Is Launching a Bank Stablecoin. Should You Buy FI Stock Here?
Fiserv (FI) shares are inching up on Monday after the financial technology company announced plans of launching its own stablecoin (FIUSD) by the end of 2025. In its press release, the financial technology giant said FIUSD will be integrated into its 'existing banking and payments infrastructure' over the next six months. The Next Trillion-Dollar Boom? 3 Stocks to Buy with 300 Million Humanoid Robots on the Horizon. Is Tesla a Buy or Sell as TSLA Stock Zooms on Austin Robotaxi Launch? These 3 Stocks Have Been Hot in 2025. Should You Sell Them Now Before It's Too Late? Get exclusive insights with the FREE Barchart Brief newsletter. Subscribe now for quick, incisive midday market analysis you won't find anywhere else. Despite today's gain, Fiserv stock is down more than 25% versus its year-to-date high. On Monday, the NYSE-listed firm said it has partnered with Circle (CRCL), Paxos, and even Solana to roll out a new digital asset platform powered by FIUSD. Additionally, Fiserv has teamed up with PayPal (PYPL) to make its stablecoin interoperable with PYUSD and make it incrementally easier for 'consumers and businesses to move funds domestically and internationally.' The development is largely positive for FI shares as it positions the multinational to capitalize on continued momentum in the stablecoin market that Seaport Research believes has already hit $260 billion in market cap. Following the Senate's approval of the GENIUS Act last week, the investment firm expects the stablecoin market to scale rapidly and hit a $500 billion valuation by the end of next year and up to $2.0 trillion longer term. TD Cowen dubbed the FIUSD announcement a 'positive indicator' as it reiterated its 'Buy' rating on Fiserv stock on Monday. In its research note, the investment firm said FI's plans of launching a stablecoin signal its 'ability to innovate rapidly.' Additionally, the fintech is primed to 'leverage central positioning between financial institutions and merchants to bridge traditional and emerging payment systems,' it added. TD Cowen analysts currently have a $233 price objective on Fiserv shares that indicates potential upside of another 40%. Other Wall Street analysts also see FI shares as potentially undervalued and recommend loading up on them at current levels. According to Barchart, the consensus rating on Fiserv stock currently sits at 'Strong Buy' with the mean target of about $220 indicating potential upside of more than 30% from here. On the date of publication, Wajeeh Khan did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on
Yahoo
3 days ago
- Business
- Yahoo
This Nuclear Energy Stock Just Got a Big Government Boost. Should You Buy It Here?
Centrus Energy (LEU) shares inched up on Friday after the nuclear energy company secured an extension on its government contract to produce High-Assay, Low-Enriched Uranium (HALEU). LEU's press release valued the one-year extension at about $110 million, adding that the Department of Energy (DOE) has the option to extend that contract for up to eight more years. Dear Tesla Stock Fans, Mark Your Calendars for June 30 3 ETFs with Dividend Yields of 12% or Higher for Your Income Portfolio This Options Tool Can Show You How to Trade Tesla Stock Ahead of Robotaxi Day Stop Missing Market Moves: Get the FREE Barchart Brief – your midday dose of stock movers, trending sectors, and actionable trade ideas, delivered right to your inbox. Sign Up Now! Including today's gain, Centrus Energy stock is up more than 280% versus its low set in early April. The HALEU contract extension is rather meaningful for Centrus Energy stock as it ensures continued visibility into future revenues. Additionally, this government extension reinforces the clean energy firm's pivotal role in restoring the country's ability to enrich uranium (UXM25) as well. With up to eight additional years of production still on the table, the DOE deal positions LEU as a long-term strategic partner in fueling next-generation nuclear reactors. As global interest in clean, secure energy intensifies, partly due to rapidly increasing demand from AI – Maryland-based Centrus stands to benefit from both commercial and national security-driven demand for HALEU. That makes LEU shares more attractive for long-term growth investors. Despite its meteoric run in recent months, Evercore ISI analysts are convinced that Centrus Energy stock has further room to the upside. Earlier this week, the investment firm reiterated its 'Outperform' rating on the clean energy stock and raised its price target to $205, which indicates potential upside of another 8.5% from current levels. Evercore ISI remains positive on LEU shares mostly because Centrus is the only company that the Nuclear Regulatory Commission has licensed so far for HALEU production. According to its analysts, the U.S. must 'unleash its advanced nuclear energy' to win the AI race. Other Wall Street analysts are nowhere near as constructive on LEU stock as Evercore ISI since it's already pricing in a lot of the good news. While the consensus rating on Centrus Energy remains at 'Strong Buy,' the mean target of about $157 indicates potential 'downside' of as much as 17% from here. On the date of publication, Wajeeh Khan did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on
